News & Events
Keep up to date with Isogenica’s latest news on collaborations, Press Releases, Events and VHH antibody resources.
Isogenica turns 25: Our journey
We’ve come a long way over the past quarter century, from our early years as a therapeutic peptide discovery company to specialising in VHH antibodies. Here’s the story…
Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship
UK-based antibody engineering experts Isogenica are proud to announce a new collaboration with the Frederick National Laboratory for Cancer Research in Maryland USA.
Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform
Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display technology in support of advancing...
Isogenica are always looking to learn and connect at upcoming events and conferences.
Due to their unique characteristics, VHH are promising candidates for a range of application areas including intracellular targeting and even across the Blood Brain Barrier (BBB). Discover all the benefits in using VHH in different applications.
CIS display, a DNA-based in vitro selection technology for therapeutic peptides
CIS display is a DNA-based in vitro display technology that enables the display and selection of peptides and proteins from extremely large libraries…
CIS display: In vitro selection of peptides from libraries of protein–DNA complexes
PNAS published February 23, 2004. 101 (9) 2806-2810
Webinars are a great source for the latest activities at Isogenica. Hear all about the newest applications of VHH.
Register for Isogenica's upcoming webinar Join Isogenica for the upcoming webinar with Nature on 'VHH as building blocks for immune and tumour cell-targeting', presented by Isogenica's CSO Bill...
Catch up with Isogenica’s news and activies through the latest Newsletters.
📣 Synthetic libraries are our forte and here’s why…
This edition we’re talking synthetic libraries: read on to see how we can save up to 8 months on immunisation alone compared with traditional approaches. Since November we’ve seen Dave attend Genesis in London, Ben go to PEGS, Barcelona, and Marion off to CAR-T, London. March will see our MRC iCASE PhD student, Natasha Spena continue her project at the University of Leicester. We’re proud to announce a new partnership with Arvinas, and finally, we ask: was our Director of Business Development, Dave Mead, correct about his biopharma predictions for 2023? And look to his predictions for 2023.
Small is beautiful – VHHs for next generation cell therapies
We’re experts on VHH antibodies. Read on to discover the advantages of using VHHs in CAR targeting, our recently launched ISOXTEND® technology, and how our VHHs are being tested in a potential new therapy for heart failure. We’re also delighted to announce that Marion Cubitt, our Director of Discovery, has been awarded a place on a prestigious RAEng scale-up accelerator programme.
Creating the next generation of immunotherapies
Immunotherapy has transformed the cancer treatment landscape in recent years, harnessing the power of the immune system to target cancer cells. However, checkpoint inhibitor drugs don’t work for all patients, so the hunt is on for more targeted and personalised therapies that directly engage immune cells with cancer cells.
Isogenica Launches A New Library Boosting Outputs For Vhh Antibody Discovery
Introducing VHHantage™ allowing maximised diversity humanised VHH binders with significantly reduced liabilties, allowing the efficient discovery developable antibodies.
Isogenica Vhh Bi And Multispecific Plugandplay Platform
Isogenica have developed fully synthetic, in vitro plugandplay cassettebased approach to efficiently generate combinations of bi and trispecific VHH, exemplified in in vitro studies.
Upcoming Nature Webinar: VHH as building blocks for immune and tumour cell-targeting
Tune in to hear Isogenica’s CSO Dr Bill Eldridge describe applications of naturally monovalent antibody domain structure combined to generate the next generation of multi-specific biologics.
Isogenica Is Attending Bio Digital 2021
Meet David Mead, Director of Business Development and Associate Director of Marketing, Dr Mandeep Sehmi at the BIO International Convention Digital 2021 June 10-11 & 14-18, to learn the latest developments of VHH single domain antibodies to tumour targets.
Using Llama-vhh To Optimize T-cell Mediated Immunotherapies
Listen to Senior Director of Antibody Discovery Dr Ed McGowan and his thorough review of the applications of VHH single domain antibodies in CAR-T and T cell engagers.
Dr Bjorn Cochlovius appointed as Chairman of Isogenica Board of Directors
Isogenica has announced today that Jan-Olof Lundin, Non-Executive Chairman of the Board of Directors (the “Board”) will retire from the Board effective 31 December 2019.
Nature Communications publishes UMC Utrecht and Isogenica research on VHHmediated targeting of LRP5 and LRP6
Under a collaboration between Isogenica and scientists at the Oncode Institute and University Medical Center Utrecht, led by Professor Madelon Maurice, Isogenica’s fully synthetic, highly diverse LlamdA™ library was screened for Wnt pathway inhibitors using CIS Display, the company’s in vitro library selection system.